ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

Find A Clinical Trial

Disease Type: Multiple Myeloma

Trial ID OP-110
Sponsor ID SEAPORT

An Expanded Access Program (EAP) Protocol for Melphalan Flufenamide (Melflufen) in Combination with Dexamethasone in Patients with Triple Class Refractory (TCR) Multiple Myeloma

Principal Investigator
Mitul Gandhi, MD
5 Locations
Trial ID D7900C00001
Sponsor ID

A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma

Principal Investigator
Mitul Gandhi, MD
Trial ID 19247
Sponsor ID Janssen

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Principal Investigator
Mitul Gandhi, MD
5 Locations
Trial ID 19021
Sponsor ID Incye/IQVIA

A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma (INCB 01158-206)

Principal Investigator
Dipti Patel-Donnelly, MD
Trial ID 18-255-02
Sponsor ID Nektar Therapeutics

A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-255 AS A SINGLE AGENT IN RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES AND IN COMBINATION WITH DARATUMUMAB AS A SALVAGE REGIMEN FOR MULTIPLE MYELOMA

Principal Investigator
Gregory J. Orloff, MD
Trial ID 19064
Sponsor ID

A PHASE Ia/Ib OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF TIRAGOLUMAB AS A SINGLE AGENT AND IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA, AND AS A SINGLE AGENT AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.(GO41036)

Principal Investigator
Gregory J. Orloff, MD
Trial ID MMRC-085
Sponsor ID MMRC-085

Myeloma-Developing Regimens Using Genomics (MyDRUG)(Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen)

Principal Investigator
Gregory J. Orloff, MD
5 Locations
Trial ID Cartesian 2415988
Sponsor ID Cartesian 2415988

Autologous CD8+ T-cells Transiently Expressing an Anti-BCMA CAR in Patients With Myeloma

Principal Investigator
Gregory J. Orloff, MD
Trial ID ADU-CL-16
Sponsor ID

A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults with Relapsed or Refractory Multiple Myeloma

Trial ID 15-179
Sponsor ID

A Phase 2 Single Arm Study of Elotuzumab in Combination with Pomalidomide and Low Dose Dexamethasone (EPd) in Patient’s with Multiple Myeloma Relapsed or Refractory to Prior Treatment with Lenalidomide (CA204142).

Principal Investigator
Gregory J. Orloff, MD
5 Locations